OncoMatch/Clinical Trials/NCT06179160
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Is NCT06179160 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for solid tumors.
Treatment: INCB161734 · Cetuximab · Retifanlimab · GEMNabP · mFOLFIRINOX · FOLFOX · FOLFIRI · INCA33890 — This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Biomarker criteria
Required: KRAS g12d mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: kras g12d inhibitor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Hospital · Phoenix, Arizona
- Stanford University · Palo Alto, California
- UCLA Healthcare Hematology-Oncology · Santa Monica, California
- Sarah Cannon Research Institue At Healthone · Denver, Colorado
- Florida Cancer Specialists · Sarasota, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify